AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25495720 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 714
Study 23657457 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfasts prepared with virgin olive oil (400 μg mL(‐1) of phenolic compounds)
Number of subjects: 0
Study 23657457 — intervention group
Group type: COMPARATOR
Intervention: Breakfasts prepared with sunflower oils (pure, enriched with dimethylsiloxane, and enriched with phenolic compounds)
Number of subjects: 0
Study 20735877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato purée (70 g)
Number of subjects: 19
Study 20735877 — intervention group
Group type: COMPARATOR
Intervention: Control (buttered roll without tomato purée)
Number of subjects: 19
Study 19465371 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy, exercise, and intermittent cervical traction (MTEXTraction group)
Number of subjects: 81
Study 19465371 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy, exercise, and sham intermittent cervical traction (MTEX group)
Number of subjects: 81
Study 17555561 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 34
Study 17555561 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 34
Study 17555561 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Anastrozole and Letrozole
Number of subjects: 34
Study 15223728 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50-100 mg o.d.
Number of subjects: 40
Study 15223728 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5-25 mg o.d.
Number of subjects: 40
Study 15223728 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 11966693 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-contact dithranol cream followed by clobetasol-17-propionate ointment 5 days per week
Number of subjects: 12
Study 11966693 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-contact dithranol cream followed by vehicle of clobetasol-17-propionate ointment
Number of subjects: 12
Study 11966693 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol-17-propionate ointment 5 days per week
Number of subjects: 12
Study 9809891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 741
Study 9809891 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 741
Study 7714225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone 300 mg plus intravenous triazolam
Number of subjects: 16
Study 7714225 — intervention group
Group type: COMPARATOR
Intervention: Intravenous triazolam plus oral placebo
Number of subjects: 16
Study 2760949 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST
Number of subjects: 911
Study 2760949 — intervention group
Group type: COMPARATOR
Intervention: No‐MAST
Number of subjects: 911
Study 180197 — intervention group
Group type: EXPERIMENTAL
Intervention: Local applications of human leukocyte interferon (3-4 X 10(4) units per day)
Number of subjects: 73
Study 180197 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocautery plus human leukocyte interferon
Number of subjects: 73
Study 180197 — intervention group
Group type: COMPARATOR
Intervention: Thermocautery plus mock human leukocyte interferon
Number of subjects: 73
Study 31352597 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned food
Number of subjects: 20
Study 31352597 — intervention group
Group type: COMPARATOR
Intervention: Fresh food
Number of subjects: 20
Study 25056368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/day
Number of subjects: 236
Study 22057896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with CoQ (Med + CoQ diet)
Number of subjects: 20
Study 22057896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20
Study 22057896 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid‐rich diet (SFA diet)
Number of subjects: 20
Study 21422864 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic-assisted vaginal hysterectomy
Number of subjects: 100
Study 21422864 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic-assisted vaginal hysterectomy
Number of subjects: 100
Study 19735908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing peptide; duration: 1 month
Number of subjects: 0
Study 19735908 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic antigen I/II peptide
Number of subjects: 0
Study 19735908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16790625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg bolus over 10 min, followed by continuous infusion of 0.5 microg.kg(‐1).h(‐1))
Number of subjects: 30
Study 16790625 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 16790625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study 15609652 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration prophylaxis with 4 g of cefmetazole sodium for 2 days
Number of subjects: 40
Study 15609652 — intervention group
Group type: COMPARATOR
Intervention: Long-duration prophylaxis with 14 g of cefmetazole sodium for 7 days
Number of subjects: 40
Study 11603137 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.5% lignocaine and 50 mg tramadol (group B)
Number of subjects: 54
Study 11603137 — intervention group
Group type: COMPARATOR
Intervention: 30 mL 0.5% lignocaine and 1 mL normal saline (group A)
Number of subjects: 54
Study 9600792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate treatment
Number of subjects: 141
Study 9600792 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal period after ibandronate treatment
Number of subjects: 141
Study 8083112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate mouth washing 1 g six times daily during irradiation (n = 20)
Number of subjects: 40
Study 8083112 — intervention group
Group type: COMPARATOR
Intervention: Placebo washing (n = 20)
Number of subjects: 40
Study 8083112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate mouth washing
Number of subjects: 40
Study 2503553 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lysine-aspirin
Number of subjects: 11
Study 2503553 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lysine-aspirin with terfenadine premedication
Number of subjects: 11
Study 2503553 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 11
Study 955765 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care patients after surgical procedures
Number of subjects: 0
Study 955765 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31958285 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercise programme (30-min daily for 12 weeks)
Number of subjects: 62
Study 31735362 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1461
Study 29946179 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg daily
Number of subjects: 124
Study 29946179 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin once weekly
Number of subjects: 124
Study 26321749 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation (25 patients)
Number of subjects: 40
Study 26321749 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (15 patients)
Number of subjects: 40
Study 24461029 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin formulation with hydrophilic carrier, cellulosic derivatives and natural antioxidants (CHC)
Number of subjects: 0
Study 24461029 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin phytosome formulation (CP)
Number of subjects: 0
Study 24461029 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation with volatile oils of turmeric rhizome (CTR)
Number of subjects: 0
Study 24461029 — intervention group
Group type: COMPARATOR
Intervention: Unformulated standard curcumin (CS)
Number of subjects: 0
Study 22124354 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing energy drink (179 mg)
Number of subjects: 13
Study 22124354 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 13
Study 21152030 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxyamphetamine (MDA)
Number of subjects: 0
Study 21152030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17414983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-level instrumented fusions using lamina autograft and demineralized bone matrix (Osteofil/ICM)
Number of subjects: 140
Study 17414983 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-level instrumented fusions using lamina autograft and demineralized bone matrix (Osteofil/ICM)
Number of subjects: 140
Study 17414983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 1-level and 2-level fusions
Number of subjects: 140
Study 17414983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-level fusions
Number of subjects: 140
Study 17414983 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-level fusions
Number of subjects: 140
Study 16352794 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels >80 pg/mL at study entry
Number of subjects: 4497
Study 16352794 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels >80 pg/mL at 4 months
Number of subjects: 4497
Study 16352794 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels >80 pg/mL at 12 months
Number of subjects: 4497
Study 16352794 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly elevated BNP levels at 4 months
Number of subjects: 4497
Study 16352794 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels <80 pg/mL at study entry and <80 pg/mL at 4 months
Number of subjects: 4497
Study 11926785 — intervention group
Group type: EXPERIMENTAL
Intervention: Split treatment (human regular insulin at dinner and NPH insulin at bedtime)
Number of subjects: 22
Study 11926785 — intervention group
Group type: COMPARATOR
Intervention: Mixed treatment (a mixture of human regular and NPH insulin administered before dinner)
Number of subjects: 22
Study 11926785 — intervention group
Group type: EXPERIMENTAL
Intervention: Split treatment
Number of subjects: 22
Study 11926785 — intervention group
Group type: COMPARATOR
Intervention: Mixed treatment
Number of subjects: 22
Study 10426343 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone (vaginal cream)
Number of subjects: 12
Study 10426343 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study 7768558 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (16 nmol over 3 minutes, then 16 pmol/kg per minute)
Number of subjects: 9
Study 7768558 — intervention group
Group type: COMPARATOR
Intervention: Saline (as vehicle)
Number of subjects: 9
Study 2261941 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 445
Study 2261941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 540460 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg of long-acting propranolol
Number of subjects: 2
Study 540460 — intervention group
Group type: COMPARATOR
Intervention: 160 mg of standard propranolol
Number of subjects: 2
Study 540460 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of sotalol
Number of subjects: 2
Study 540460 — intervention group
Group type: COMPARATOR
Intervention: 160 mg of oxprenolol
Number of subjects: 2
Study 540460 — intervention group
Group type: COMPARATOR
Intervention: 160 mg of slow-release oxprenolol
Number of subjects: 2
Study 31928088 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Fracture Unit (HFU)
Number of subjects: 276
Study 31928088 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 276
Study 31805840 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative group therapy
Number of subjects: 85
Study 28573683 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 0
Study 28573683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25201555 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 56
Study 25201555 — intervention group
Group type: COMPARATOR
Intervention: No abdominal binder (control)
Number of subjects: 56
Study 24782235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender scent
Number of subjects: 117
Study 24782235 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music
Number of subjects: 117
Study 24782235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scent and music
Number of subjects: 117
Study 24782235 — intervention group
Group type: COMPARATOR
Intervention: No scent and music (control condition)
Number of subjects: 117
Study 22950513 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% resting motor threshold rTMS
Number of subjects: 60
Study 22950513 — intervention group
Group type: COMPARATOR
Intervention: 20% resting motor threshold rTMS
Number of subjects: 60
Study 18615497 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐G/antidepressant combination
Number of subjects: 45
Study 18615497 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant alone
Number of subjects: 45
Study 17501760 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b
Number of subjects: 52
Study 17501760 — intervention group
Group type: COMPARATOR
Intervention: Conventional IFN alpha‐2b
Number of subjects: 52
Study 15241906 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2, a 2‐step self‐etching primer (n = 46)
Number of subjects: 90
Study 15241906 — intervention group
Group type: EXPERIMENTAL
Intervention: One Coat Bond, a one bottle total‐etch system applied with one coat (n = 46)
Number of subjects: 90
Study 15241906 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop, a 1‐step self‐etching primer ('all‐in‐one') (n = 52)
Number of subjects: 90
Study 15241906 — intervention group
Group type: COMPARATOR
Intervention: Sclerotic lesions
Number of subjects: 90
Study 15241906 — intervention group
Group type: COMPARATOR
Intervention: Non-sclerotic lesions
Number of subjects: 90
Study 15241906 — intervention group
Group type: COMPARATOR
Intervention: Diamond bur-roughened lesions
Number of subjects: 90
Study 15241906 — intervention group
Group type: COMPARATOR
Intervention: Non-roughened lesions
Number of subjects: 90
Study 11755018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative DNA damage assessment in AD patients
Number of subjects: 0
Study 11755018 — intervention group
Group type: COMPARATOR
Intervention: Oxidative DNA damage assessment in age-matched controls
Number of subjects: 0
Study 11755018 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair capacity assessment in AD patients
Number of subjects: 0
Study 11755018 — intervention group
Group type: COMPARATOR
Intervention: Repair capacity assessment in age-matched controls
Number of subjects: 0
Study 9673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial working memory tasks
Number of subjects: 0
Study 9673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Object working memory tasks
Number of subjects: 0
Study 9673660 — intervention group
Group type: COMPARATOR
Intervention: Perceptual control tasks
Number of subjects: 0
Study 9673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory tasks
Number of subjects: 0
Study 9673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape task
Number of subjects: 0
Study 10690161 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich, protein-poor (CR/PP) diet
Number of subjects: 43
Study 10690161 — intervention group
Group type: COMPARATOR
Intervention: Protein-rich, carbohydrate-poor (PR/CP) diet
Number of subjects: 43
Study 10690161 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollable stress
Number of subjects: 43
Study 10690161 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress tasks
Number of subjects: 43
Study 10690161 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, stress-proneness and stress-controllability interaction
Number of subjects: 43
Study 1995917 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat intake (77 g per day)
Number of subjects: 56337
Study 12265806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydron-coated Spring Coil
Number of subjects: 464
Study 12265806 — intervention group
Group type: COMPARATOR
Intervention: Plain Spring Coil
Number of subjects: 464
Study 31565242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 747
Study 31565242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 747
Study 31565242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 747
Study 29381543 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPB‐T45K
Number of subjects: 46
Study 29381543 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study 26787016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles
Number of subjects: 0
Study 26787016 — intervention group
Group type: COMPARATOR
Intervention: Custom spectacles
Number of subjects: 0
Study 24735885 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 + PYY3-36
Number of subjects: 25
Study 24735885 — intervention group
Group type: COMPARATOR
Intervention: PYY3-36
Number of subjects: 25
Study 24735885 — intervention group
Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 25
Study 24735885 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 25
Study 22403770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention
Number of subjects: 3473
Study 22403770 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intervention
Number of subjects: 3473
Study 22403770 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 3473
Study 20088721 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 179
Study 20088721 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 179
Study 20088721 — intervention group
Group type: COMPARATOR
Intervention: Conversion from spinal to general anaesthesia
Number of subjects: 179
Study 20088721 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation
Number of subjects: 179
Study 17901162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led intermediate care package including initial pulmonary rehabilitation, self‐management education, written COPD action plan, monthly telephone calls, and 3 monthly home visits by a specialist nurse for 2 years
Number of subjects: 122
Study 17901162 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 122
Study 16823355 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrins ingestion (0.7 g x kg(-1) body mass)
Number of subjects: 10
Study 16823355 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate free placebo
Number of subjects: 10
Study 12798791 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 12798791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10590187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy (81 or 325 mg)
Number of subjects: 32
Study 9547130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 9547130 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 9547130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9547130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (general)
Number of subjects: 0
Study 8396749 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg evening dose for 8 weeks
Number of subjects: 26
Study 8396749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3453200 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit Kit (self-administered smoking cessation program)
Number of subjects: 207
Study 3453200 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (Control group)
Number of subjects: 207
Study 31689737 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigation
Number of subjects: 38
Study 31689737 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 38
Study 29457363 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-incision, three-port laparoscopic appendectomy (DILA)
Number of subjects: 60
Study 29457363 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy (CLA)
Number of subjects: 60
Study 27447719 — intervention group
Group type: EXPERIMENTAL
Intervention: MF102 4 g/day
Number of subjects: 30
Study 24445656 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 74
Study 24445656 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 74
Study 22448994 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus verbal feedback
Number of subjects: 54
Study 22448994 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal feedback
Number of subjects: 54
Study 22448994 — intervention group
Group type: COMPARATOR
Intervention: Experiential feedback
Number of subjects: 54
Study 19949360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine reassortant rotavirus vaccine
Number of subjects: 2956
Study 19949360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2956
Study 17924887 — intervention group
Group type: EXPERIMENTAL
Intervention: Format A (two pieces of strength information different from those in the instruction)
Number of subjects: 0
Study 17924887 — intervention group
Group type: EXPERIMENTAL
Intervention: Format B (all three pieces in a random sequence)
Number of subjects: 0
Study 17924887 — intervention group
Group type: COMPARATOR
Intervention: Format C (all three pieces in a fixed sequence)
Number of subjects: 0
Study 15564386 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy with an audiotape of classical music and ocean sounds during CNB
Number of subjects: 143
Study 15564386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg of alprazolam administered orally 15 minutes before CNB
Number of subjects: 143
Study 15564386 — intervention group
Group type: COMPARATOR
Intervention: No anxiety intervention (usual care group)
Number of subjects: 143